Reuters logo
BRIEF-Pharma Mar to start pivotal phase III study with lurbinectedin for endometrial cancer
May 18, 2017 / 11:24 AM / 7 months ago

BRIEF-Pharma Mar to start pivotal phase III study with lurbinectedin for endometrial cancer

May 18 (Reuters) - PHARMA MAR SA:

* AFTER POSITIVE RESULTS OBTAINED IN ENDOMETRIAL CANCER WITH LURBINECTEDIN PLANS TO INITIATE PIVOTAL PHASE III STUDY Source text: bit.ly/2rudx52

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below